Skip to main content
Top
Published in: Dermatology and Therapy 1/2014

Open Access 01-06-2014 | Original Research

Acne Subject Preference for Pump Over Tube for Dispensing Fixed-Dose Combination Adapalene 0.1%–Benzoyl Peroxide 2.5% Gel

Author: Maria J. Rueda

Published in: Dermatology and Therapy | Issue 1/2014

Login to get access

Abstract

Introduction

Acne is a chronic inflammatory disease. Key to a patient’s success on fixed-dose adapalene–benzoyl peroxide (BPO) gel is ensuring adherence. Use of a pump system to deliver a pre-measured amount of gel with each pressure enables application of a more consistent dose vs. the tube, which should improve adherence. In the present study, we evaluate patient preference for two different containers for dispensing adapalene–BPO gel.

Methods

In this 15-day, open-label study, 300 subjects were asked to treat their acne using fixed-dose adapalene 0.1%–BPO 2.5% gel dispensed in either a tube or a pump once-daily for up to 7 days. At week 1, subjects switched to the alternative packaging design for the same timeframe. At the end of the treatment period, subjects were asked to complete a subject preference survey.

Results

Among subjects completing the survey (n = 291), 79.0% (n = 230) preferred the pump for dispensing adapalene–BPO gel and 21.0% (n = 61) preferred the tube (p < 0.001). The top three characteristics of the pump were that it was easy to use (89.0%; n = 259/291), clean (73.2%; n = 213/291) and convenient (69.4%; n = 202/291). When asked to rate their experience with using the pump, 91.8% (n = 267/291; p < 0.001) of subjects reported being satisfied on a self-assessment scale. The majority of subjects stated they would tell their doctor about their preference for the pump next time adapalene–BPO gel was prescribed (76.6%; n = 223/291; p < 0.001) and would prefer the pump if both containers cost the same amount (80.1%; n = 233/291; p < 0.001).

Conclusion

Patients prefer using a pump instead of a tube to dispense adapalene–BPO gel. This delivery mechanism helps to ensure consistent application and thus may improve patient adherence to the prescribed acne treatment regimen.
Appendix
Available only for authorised users
Literature
1.
go back to reference Thiboutot D, Gollnick H, Bettoli V, et al. New insights into the management of acne: an update from the Global Alliance to Improve Outcomes in Acne Group. J Am Acad Dermatol. 2009;60:S1–50.PubMedCrossRef Thiboutot D, Gollnick H, Bettoli V, et al. New insights into the management of acne: an update from the Global Alliance to Improve Outcomes in Acne Group. J Am Acad Dermatol. 2009;60:S1–50.PubMedCrossRef
2.
go back to reference Gollnick HPM, Finlay AY, Shear N. Global Alliance to Improve Outcomes in Acne. Can we define acne as a chronic disease? If so, how and when? Am J Clin Dermatol. 2008;9:279–84.PubMedCrossRef Gollnick HPM, Finlay AY, Shear N. Global Alliance to Improve Outcomes in Acne. Can we define acne as a chronic disease? If so, how and when? Am J Clin Dermatol. 2008;9:279–84.PubMedCrossRef
3.
go back to reference Thiboutot D, Dréno B, Layton A. Acne counseling to improve adherence. Cutis. 2008;81:81–6.PubMed Thiboutot D, Dréno B, Layton A. Acne counseling to improve adherence. Cutis. 2008;81:81–6.PubMed
4.
go back to reference Tan JK, Balagurusamy M, Fung K, et al. Effect of quality of life impact and clinical severity on adherence to topical acne treatment. J Cutan Med Surg. 2009;13:204–8.PubMed Tan JK, Balagurusamy M, Fung K, et al. Effect of quality of life impact and clinical severity on adherence to topical acne treatment. J Cutan Med Surg. 2009;13:204–8.PubMed
5.
go back to reference Dréno B, Thiboutot D, Gollnick H, et al. Large-scale worldwide observational study of adherence with acne therapy. Int J Dermatol. 2010;49:448–56.PubMedCrossRef Dréno B, Thiboutot D, Gollnick H, et al. Large-scale worldwide observational study of adherence with acne therapy. Int J Dermatol. 2010;49:448–56.PubMedCrossRef
6.
go back to reference Zaghloul SS, Cunliffe WJ, Goodfield MJ. Objective assessment of compliance with treatments in acne. Br J Dermatol. 2005;152:1015–21.PubMedCrossRef Zaghloul SS, Cunliffe WJ, Goodfield MJ. Objective assessment of compliance with treatments in acne. Br J Dermatol. 2005;152:1015–21.PubMedCrossRef
7.
go back to reference Kellett N, West F, Finlay AY. Conjoint analysis: a novel, rigorous tool for determining patient preferences for topical antibiotic treatment for acne. A randomised controlled trial. Br J Dermatol. 2006;154:524–32.PubMedCrossRef Kellett N, West F, Finlay AY. Conjoint analysis: a novel, rigorous tool for determining patient preferences for topical antibiotic treatment for acne. A randomised controlled trial. Br J Dermatol. 2006;154:524–32.PubMedCrossRef
8.
go back to reference Fried R, Nighland M. Acne quality of life and patient satisfaction following treatment with tretinoin pump. J Drugs Dermatol. 2009;8:1080–5.PubMed Fried R, Nighland M. Acne quality of life and patient satisfaction following treatment with tretinoin pump. J Drugs Dermatol. 2009;8:1080–5.PubMed
9.
go back to reference Eichenfield LF, Nighland M, Rossi AB, et al. Phase 4 study to assess tretinoin pump for the treatment of facial acne. J Drugs Dermatol. 2008;7:1129–36.PubMed Eichenfield LF, Nighland M, Rossi AB, et al. Phase 4 study to assess tretinoin pump for the treatment of facial acne. J Drugs Dermatol. 2008;7:1129–36.PubMed
10.
go back to reference Pariser D. Adapalene 0.1% and benzoyl peroxide 2.5% combination gel for the treatment of acne vulgaris. Expert Rev Dermatol. 2010;5:385–91.CrossRef Pariser D. Adapalene 0.1% and benzoyl peroxide 2.5% combination gel for the treatment of acne vulgaris. Expert Rev Dermatol. 2010;5:385–91.CrossRef
11.
go back to reference Del Rosso JQ. A qualitative and quantitative assessment of the application and use of topical acne medication by patients. Cutis. 2005;76:109–13.PubMed Del Rosso JQ. A qualitative and quantitative assessment of the application and use of topical acne medication by patients. Cutis. 2005;76:109–13.PubMed
12.
go back to reference Galderma (2014). Packaging agreement Epiduo DS—non US. Updated 16 January 2014. Galderma (2014). Packaging agreement Epiduo DS—non US. Updated 16 January 2014.
13.
go back to reference Galderma (2011). Pump functionality testing report: Epiduo® (adapalene and benzoyl peroxide) gel, 0.1%/2.5% in the 45 g (DS). Document no: 1.BD.05.PMF.0025.R01. Galderma (2011). Pump functionality testing report: Epiduo® (adapalene and benzoyl peroxide) gel, 0.1%/2.5% in the 45 g (DS). Document no: 1.BD.05.PMF.0025.R01.
14.
go back to reference Poulin Y, Sanchez NP, Bucko A, et al. A 6-month maintenance therapy with adapalene–benzoyl peroxide gel prevents relapse and continuously improves efficacy among patients with severe acne vulgaris: results of a randomized controlled trial. Br J Dermatol. 2011;164:1376–82.PubMedCrossRef Poulin Y, Sanchez NP, Bucko A, et al. A 6-month maintenance therapy with adapalene–benzoyl peroxide gel prevents relapse and continuously improves efficacy among patients with severe acne vulgaris: results of a randomized controlled trial. Br J Dermatol. 2011;164:1376–82.PubMedCrossRef
15.
go back to reference Tan J, Stein Gold L, Schlessinger J, et al. Short-term combination therapy and long-term relapse prevention in the treatment of severe acne vulgaris. J Drugs Dermatol. 2012;11:174–80.PubMed Tan J, Stein Gold L, Schlessinger J, et al. Short-term combination therapy and long-term relapse prevention in the treatment of severe acne vulgaris. J Drugs Dermatol. 2012;11:174–80.PubMed
16.
go back to reference Stein Gold L, Tan J, Cruz-Santana A, et al. A North American study of adapalene–benzoyl peroxide combination gel in the treatment of acne. Cutis. 2009;84:110–6. Stein Gold L, Tan J, Cruz-Santana A, et al. A North American study of adapalene–benzoyl peroxide combination gel in the treatment of acne. Cutis. 2009;84:110–6.
17.
go back to reference Gollnick HP, Draelos Z, Glenn MJ, et al. Adapalene–benzoyl peroxide, a unique fixed-dose combination topical gel for the treatment of acne vulgaris: a transatlantic, randomized, double-blind, controlled study in 1670 patients. Br J Dermatol. 2009;161:1180–9.PubMedCrossRef Gollnick HP, Draelos Z, Glenn MJ, et al. Adapalene–benzoyl peroxide, a unique fixed-dose combination topical gel for the treatment of acne vulgaris: a transatlantic, randomized, double-blind, controlled study in 1670 patients. Br J Dermatol. 2009;161:1180–9.PubMedCrossRef
18.
go back to reference Pariser DM, Westmoreland P, Morris A, Gold MH, Liu Y, Graeber M. Long-term safety and efficacy of a unique fixed-dose combination gel of adapalene 0.1% and benzoyl peroxide 2.5% for the treatment of acne vulgaris. J Drugs Dermatol. 2007;6:899–905.PubMed Pariser DM, Westmoreland P, Morris A, Gold MH, Liu Y, Graeber M. Long-term safety and efficacy of a unique fixed-dose combination gel of adapalene 0.1% and benzoyl peroxide 2.5% for the treatment of acne vulgaris. J Drugs Dermatol. 2007;6:899–905.PubMed
19.
go back to reference Stein Gold L, Cruz A, Eichenfield L, et al. Effective and safe combination therapy for severe acne vulgaris: a randomized, vehicle-controlled, double-blind study of adapalene 0.1%–benzoyl peroxide 2.5% fixed-dose combination gel with doxycycline hyclate 100 mg. Cutis. 2010;85:94–104. Stein Gold L, Cruz A, Eichenfield L, et al. Effective and safe combination therapy for severe acne vulgaris: a randomized, vehicle-controlled, double-blind study of adapalene 0.1%–benzoyl peroxide 2.5% fixed-dose combination gel with doxycycline hyclate 100 mg. Cutis. 2010;85:94–104.
20.
go back to reference Dréno B, Kaufmann R, Talarico S, et al. Combination therapy with adapalene–benzoyl peroxide and oral lymecycline in the treatment of moderate to severe acne vulgaris: a multicentre, randomized, double-blind controlled study. Br J Dermatol. 2011;165:383–90.PubMedCrossRef Dréno B, Kaufmann R, Talarico S, et al. Combination therapy with adapalene–benzoyl peroxide and oral lymecycline in the treatment of moderate to severe acne vulgaris: a multicentre, randomized, double-blind controlled study. Br J Dermatol. 2011;165:383–90.PubMedCrossRef
21.
go back to reference Thiboutot DM, Weiss J, Bucko A, et al. Adapalene–benzoyl peroxide, a fixed-dose combination for the treatment of acne vulgaris: results of a multicenter, randomized double-blind, controlled study. J Am Acad Dermatol. 2007;57:791–9.PubMedCrossRef Thiboutot DM, Weiss J, Bucko A, et al. Adapalene–benzoyl peroxide, a fixed-dose combination for the treatment of acne vulgaris: results of a multicenter, randomized double-blind, controlled study. J Am Acad Dermatol. 2007;57:791–9.PubMedCrossRef
22.
go back to reference Loesche C, Pernin C, Poncet M. Adapalene 0.1% and benzoyl peroxide 2.5% as a fixed-dose combination gel is as well tolerated as the individual components alone in terms of cumulative irritancy. Eur J Dermatol. 2008;18:524–6.PubMed Loesche C, Pernin C, Poncet M. Adapalene 0.1% and benzoyl peroxide 2.5% as a fixed-dose combination gel is as well tolerated as the individual components alone in terms of cumulative irritancy. Eur J Dermatol. 2008;18:524–6.PubMed
Metadata
Title
Acne Subject Preference for Pump Over Tube for Dispensing Fixed-Dose Combination Adapalene 0.1%–Benzoyl Peroxide 2.5% Gel
Author
Maria J. Rueda
Publication date
01-06-2014
Publisher
Springer Healthcare
Published in
Dermatology and Therapy / Issue 1/2014
Print ISSN: 2193-8210
Electronic ISSN: 2190-9172
DOI
https://doi.org/10.1007/s13555-014-0054-1

Other articles of this Issue 1/2014

Dermatology and Therapy 1/2014 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.